Kyckr and Simple KYC Announce Partnership and Launch of UBO Verify
November 16, 2021 09:00 ET
|
Kyckr
SAN FRANCISCO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Kyckr Limited (ASX:KYK) (Kyckr or the Company), a B2B information services company, is pleased to announce its partnership with Simple KYC, an...
Korean Data Intelligence Trailblazer S2W Joins Membership of APWG
November 08, 2021 09:00 ET
|
APWG
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Korean cyberthreat intelligence trailblazer S2W has established a partnership with Anti-Phishing Working Group (APWG), the international...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
November 05, 2021 09:41 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
November 04, 2021 16:15 ET
|
Aprea Therapeutics
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
November 04, 2021 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
November 04, 2021 06:00 ET
|
Aptose Biosciences, Inc.
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04,...
AB Science obtient l’autorisation de l’ANSM d’initier une étude avec la molécule AB8939 dans le traitement de la leucémie myéloïde aigue (LMA)
October 18, 2021 12:14 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE OBTIENT L’AUTORISATION DE L’ANSM D'INITIER UNE ÉTUDE AVEC LA MOLECULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE AIGUË MYÉLOÏDE (LMA) SECONDE AUTORISATION POUR L'ETUDE...
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
October 18, 2021 12:14 ET
|
AB Science
PRESS RELEASE AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) SECOND AUTHORIZATION FOR...
Two Day AML/BSA Online Boot Camp, November 10th-11th, 2021
October 11, 2021 04:18 ET
|
Research and Markets
Dublin, Oct. 11, 2021 (GLOBE NEWSWIRE) -- The "AML/BSA Boot Camp" training has been added to ResearchAndMarkets.com's offering. The BSA/AML/OFAC Compliance Officer is responsible for developing,...
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
September 22, 2021 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE L’AUTORITE DE SANTÉ CANADIENNE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC SA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË...